Maria Paula Del Médico Zajac

Dr. Maria Paula Del Médico Zajac

Biotechnology Institute, INTA, Buenos Aires, Argentina
+1
orcid

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2010 in The Veterinary Journal
Verified
Journal Article
Closed access
Maria Paula Del Médico ZajacMaria Paula Del Médico Zajac
Maria Paula Del Médico Zajac
MLMaría F. Ladelfa
María F. Ladelfa
FKFiorella Kotsias
Fiorella Kotsias
BMBenoît Muylkens
Benoît Muylkens
JTJulien Thiry
Julien Thiry
SRSonia A. Romera
Sonia A. Romera

1 December 2006 in Research in Veterinary Science
Verified
Journal Article
Closed access
Maria Paula Del Médico ZajacMaria Paula Del Médico Zajac
Maria Paula Del Médico Zajac
MPM. Puntel
M. Puntel
PZP.I. Zamorano
P.I. Zamorano
ASA.M. Sadir
A.M. Sadir
SRS.A. Romera
S.A. Romera

1 January 2014 in BMC Veterinary Research
Verified
Journal Article
Open access
PDF file
SRSonia Romera
Sonia Romera
MPMariana Puntel
Mariana Puntel
VQValeria Quattrocchi
Valeria Quattrocchi
Maria Paula Del Médico ZajacMaria Paula Del Médico Zajac
Maria Paula Del Médico Zajac
PZPatricia Zamorano
Patricia Zamorano
ASAna M Sadir
Ana M Sadir
Bovine herpesvirus type 1 (BoHV-1) is the causative agent of respiratory and genital tract infections; causing a high economic loss in all continents. Use of marker vaccines in IBR eradication programs is widely accepted since it allows for protection of the animals against the disease while adding the possibility of differentiating vaccinated from infected animals.

1 August 2014 in Vaccine
Verified
Journal Article
Closed access
JOJosé Manuel Jaramillo Ortiz
José Manuel Jaramillo Ortiz
Maria Paula Del Médico ZajacMaria Paula Del Médico Zajac
Maria Paula Del Médico Zajac
FZFlavia Adriana Zanetti
Flavia Adriana Zanetti
MMMaría Paula Molinari
María Paula Molinari
MGMaría José Gravisaco
María José Gravisaco
SWSilvina Elizabeth Wilkowsky
Silvina Elizabeth Wilkowsky

7 February 2011 in BMC Veterinary Research
Verified
Journal Article
Open access
PDF file
SMSilvina S Maidana
Silvina S Maidana
MLMaría F Ladelfa
María F Ladelfa
Sandra PérezSandra Pérez
Sandra Pérez
PLPatricia M Lomónaco
Patricia M Lomónaco
Maria Paula Del Médico ZajacMaria Paula Del Médico Zajac
Maria Paula Del Médico Zajac
SRSonia A Romera
Sonia A Romera
Background: Bovine herpesvirus 5 (BoHV-5) is a member of the subfamilyAlphaherpesvirinaeresponsible for meningo-encephalitis in young cattle. The first case of bovine meningo-encephalitis associated with a herpesvirus infection was reported in Australia. The current geographical distribution of BoHV-5 infection is mainly restricted to South America, especially Brazil and Argentina. Outbreaks of BoHV-5 are regularly observed in Argentina suggesting the circulation of the virus in the bovine population.Results: Seventeen field strains of BoHV-5 isolated from 1984 to now were confirmed by differential PCR and subjected to restriction endonuclease analysis (REA). Viral DNA was cleaved with BstEII which allows the differentiation among subtypes a, b and non a, non b. According to the REA with BstEII, only one field strain showed a pattern similar to the Argentinean A663 strain (prototype of BoHV-5b). All other isolates showed a clear pattern similar to the Australian N569 strain (prototype of BoHV-5a) consistent with the subtypes observed in Brazil, the other South-American country where BoHV-5 is known to be prevalent. The genomic region of subtype b responsible for the distinct pattern was determined and amplified by PCR; specifically a point mutation was identified in glycoprotein B gene, on the BstEII restriction site, which generates the profile specific of BoHV-5b.Conclusions: This is the first report of circulation of BoHV-5a in Argentina as the prevailing subtype. Therefore the circulation of BoHV-5b was restricted to a few years in Argentina, speculating that this subtype was not able to be maintained in the bovine population. The mutation in the gB gene is associated with the difference in the restriction patterns between subtypes "a" and "b".

23 May 2016 in Viruses
Verified
Journal Article
Open access
PDF file
MHMaría Pía Holgado
María Pía Holgado
JFJuliana Falivene
Juliana Falivene
CMCynthia Maeto
Cynthia Maeto
MAMicaela Amigo
Micaela Amigo
MPMaria Fernanda Pascutti
Maria Fernanda Pascutti
MHMaría Pía Holgado
María Pía Holgado
MVA is an attenuated vector that still retains immunomodulatory genes. We have previously reported its optimization after deleting the C12L gene, coding for the IL-18 binding-protein. Here, we analyzed the immunogenicity of MVA vectors harboring the simultaneous deletion of A44L, related to steroid synthesis and A46R, a TLR-signaling inhibitor (MVAΔA44L-A46R); or also including a deletion of C12L (MVAΔC12L/ΔA44L-A46R). The absence of biological activities of the deleted genes in the MVA vectors was demonstrated. Adaptive T-cell responses against VACV epitopes, evaluated in spleen and draining lymph-nodes of C57Bl/6 mice at acute/memory phases, were of higher magnitude in those animals that received deleted MVAs compared to MVAwt. MVAΔC12L/ΔA44L-A46R generated cellular specific memory responses of higher quality characterized by bifunctionality (CD107a/b+/IFN-γ+) and proliferation capacity. Deletion of selected genes from MVA generated innate immune responses with higher levels of determining cytokines related to T-cell response generation, such as IL-12, IFN-γ, as well as IL-1β and IFN-β. This study describes for the first time that simultaneous deletion of the A44L, A46R and C12L genes from MVA improved its immunogenicity by enhancing the host adaptive and innate immune responses, suggesting that this approach comprises an appropriate strategy to increase the MVA vaccine potential.